Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00910520 · ClinicalTrials.gov registry record · Phase 3
Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 548
- Enrollment target
NCT00910520: Completed Phase 3 study, sponsored by Allergan.
NCT00910520 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 548 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00910520, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 548 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
Primary Outcome
A urinary incontinence episode is defined as an incident of involuntary loss of urine as recorded in a patient bladder diary during the 3 days before the Baseline and Week 12 study visits. A negative number change from baseline indicates a reduction in incontinence episodes (improvement).
Interventions
- DRUG normal saline
- BIOLOGICAL onabotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 548 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
What the finished NCT00910520 record still lists
NCT00910520 is an interventional study that assigns participants to a tested intervention. The registered 548 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% lower).
The record links to 0 conditions, and to 2 interventions - of which normal saline is the first listed.
NCT00910520 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00910520 about?
NCT00910520 is a clinical study titled "Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence". The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
What is the current status of trial NCT00910520?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 548 participants. The study started on 2009-09. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00910520?
The interventions under investigation include: normal saline (DRUG), onabotulinumtoxinA (BIOLOGICAL).
Who is sponsoring clinical trial NCT00910520?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00910520's enrollment target sits among peer trials
548 689th of 2000 higher than 1,312 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
- NCT02995252 · 550 participants
The HOPE Study: Characterizing Patients With Hepatitis B and C
- NCT03474913 · 550 participants
Upright MRI for Prostate Cancer Screening
- NCT04761120 · 550 participants
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia